Clinical Trial Update: Effect of QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) on Cardiac Function in COPD Patients [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating the effect of QVA149 (indacaterol/glycopyrronium) on cardiac function in COPD patients; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• QVA149 (indacaterol/glycopyrronium)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Obstructive Pulmonary Disease, COPD | Phase 4 | Status: COMPLETED | Results posted: 2018-12-03